Allspring Global Investments Holdings LLC Has $3.44 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Allspring Global Investments Holdings LLC lowered its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 91.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 21,777 shares of the biotechnology company’s stock after selling 239,511 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Sarepta Therapeutics were worth $3,441,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Mather Group LLC. bought a new position in shares of Sarepta Therapeutics in the first quarter valued at $28,000. Riggs Asset Managment Co. Inc. lifted its stake in Sarepta Therapeutics by 125.0% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 125 shares in the last quarter. New Covenant Trust Company N.A. purchased a new position in Sarepta Therapeutics during the 1st quarter worth $32,000. Principal Securities Inc. bought a new stake in shares of Sarepta Therapeutics in the 4th quarter worth $26,000. Finally, GAMMA Investing LLC raised its holdings in shares of Sarepta Therapeutics by 37.0% in the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 87 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Leerink Partners boosted their price target on shares of Sarepta Therapeutics from $165.00 to $230.00 and gave the stock an “outperform” rating in a report on Monday, June 24th. Needham & Company LLC restated a “buy” rating and issued a $235.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, June 27th. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, August 15th. BMO Capital Markets upped their price target on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research note on Monday, June 24th. Finally, Bank of America boosted their target price on shares of Sarepta Therapeutics from $166.00 to $213.00 and gave the company a “buy” rating in a report on Friday, June 21st. Three research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $186.22.

Insiders Place Their Bets

In other news, insider Bilal Arif sold 7,859 shares of the stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the transaction, the insider now directly owns 21,261 shares in the company, valued at approximately $3,467,243.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Bilal Arif sold 7,859 shares of the company’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $163.08, for a total value of $1,281,645.72. Following the completion of the sale, the insider now owns 21,261 shares of the company’s stock, valued at approximately $3,467,243.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Ryan Edward Brown sold 38,957 shares of Sarepta Therapeutics stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total transaction of $6,295,840.77. Following the completion of the transaction, the executive vice president now owns 17,129 shares in the company, valued at approximately $2,768,217.69. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Trading Down 1.1 %

Shares of Sarepta Therapeutics stock opened at $135.78 on Monday. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. Sarepta Therapeutics, Inc. has a 1 year low of $55.25 and a 1 year high of $173.25. The firm has a market cap of $12.95 billion, a PE ratio of 1,234.36 and a beta of 0.89. The company has a 50 day simple moving average of $145.03 and a two-hundred day simple moving average of $133.06.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. The company had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The firm’s revenue was up 38.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.27) EPS. Analysts expect that Sarepta Therapeutics, Inc. will post 1.47 earnings per share for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.